Market Cap 639.19M
Revenue (ttm) 296.15M
Net Income (ttm) 24.02M
EPS (ttm) N/A
PE Ratio 6.31
Forward PE 4.38
Profit Margin 8.11%
Debt to Equity Ratio -2.69
Volume 1,936,800
Avg Vol 2,607,346
Day's Range N/A - N/A
Shares Out 163.06M
Stochastic %K 71%
Beta 0.29
Analysts Sell
Price Target $6.10

Company Profile

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA name...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 617 621 7722
Fax: 617 494 0480
Address:
100 Summer Street, Suite 2300, Boston, United States
joemist1
joemist1 May. 25 at 12:59 AM
$IRWD Good evening bstrds. Are the mtha fcking shirt sellers here yet to fck up the share price? They better show up!
0 · Reply
StockTwitsGhost
StockTwitsGhost May. 24 at 5:15 PM
$IRWD Realistic PoA is 90%+. The only scenario for a CRL here is a manufacturing issue or a safety signal in the 2-5 age cohort data that nobody has flagged publicly. Neither has any visible evidence. The reality is the PDUFA shouldn’t move IRWD +/- 5% on approval or decline, but it often feel less like fundamentals are not in the drivers seat and more like a coordinated manipulation by the deeply insecure hedge fund guys with cool operator beards, elevator shoes, and a carefully curated “masculine” image for their Maine vaca homes. 🤷🏼‍♀️
0 · Reply
StockTwitsGhost
StockTwitsGhost May. 23 at 7:05 PM
$IRWD When the FDA approved the pediatric IBS-C indication in November 2025, IRWD moved roughly 9% close to close and about 15% intraday. The May PDUFA or CRL on the supplemental indication would likely pull shares up/down 8-10% given the ongoing FUD by the 🦄 brigade which includes the Maine short sellers. Also notably in November, neither AbbVie nor Ironwood issued a standalone press release for that approval either. There was no dedicated 8-K, no standalone Business Wire release, and no SEC filing on November 5 itself tied to the approval event, instead it was buried in IRWD Q3 2025 earnings press release filed as an 8-K Exhibit 99.1 on November 10, 2025. Compare that to the June 2023 pediatric FC approval, which both companies announced with dedicated PRs.
0 · Reply
revuelto
revuelto May. 23 at 10:26 AM
$IRWD extreme fud is largely priced in at these levels…approval I think is expected by the street…post June repayment the convertibles disappear cleaning up the balance sheet…this sentiment shift should get it to a more meaningful valuation (2x)…also, acquisition interest will be extremely strong after these events.
0 · Reply
noturfinancrbro
noturfinancrbro May. 23 at 6:26 AM
$IRWD do you expect any move after Pdufa Or is it already priced in,
0 · Reply
StMichaelTwits
StMichaelTwits May. 22 at 10:11 PM
$IRWD Pdufa pastries are always better in the morning with your caffe' This is getting approved.imo 💎💪
0 · Reply
StockTwitsGhost
StockTwitsGhost May. 22 at 5:28 PM
$IRWD NDA 202811/S-023 For you cyber sleuths, search NDA 202811/S-023 attention AbbVie Inc and watch for it to appear in the supplements table with an action date. Right now it shows nothing because it’s pending. The moment the FDA acts, approval or CRL, that entry will populate with an action date. The FDA database update will likely hit before or simultaneously with the AbbVie press release, and definitely before IRWD files an 8-K. It’s the most direct primary source you have. Check it Tuesday morning before the open. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
0 · Reply
StockTwitsGhost
StockTwitsGhost May. 22 at 4:03 PM
$IRWD If no action comes during business hours today, after hours is effectively off the table. The FDA issues approvals during normal business hours they don’t drop letters in the evening or on weekends. So Tuesday May 26 this is now the call. AbbVie will receive notification before Ironwood since they are the applicant so they could be sitting on a press release, holding it until Tuesday morning for a time release with IRWD for maximum market visibility. 80% Tuesday almost certainly before market open is our most likely window.
3 · Reply
UprootedData975
UprootedData975 May. 22 at 3:04 PM
$IRWD wonder when this will re-rate. even at a reasonable 6x multiple we're at double the current share price...
0 · Reply
UprootedData975
UprootedData975 May. 22 at 3:02 PM
$IRWD guessing we'll see PDUFA response Tuesday?
0 · Reply
Latest News on IRWD
Ironwood Pharmaceuticals Q1 Earnings Call Highlights

May 8, 2026, 4:14 PM EDT - 16 days ago

Ironwood Pharmaceuticals Q1 Earnings Call Highlights


Ironwood Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 17 days ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q1 2026


Ironwood Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 17 days ago

Ironwood Pharmaceuticals Earnings release: Q1 2026


Ironwood Pharmaceuticals Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 17 days ago

Ironwood Pharmaceuticals Slides: Q1 2026


Ironwood Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 17 days ago

Ironwood Pharmaceuticals Quarterly report: Q1 2026


Ironwood Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 26 days ago

Ironwood Pharmaceuticals Proxy statement: Proxy filing


Ironwood Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 26 days ago

Ironwood Pharmaceuticals Proxy statement: Proxy filing


Ironwood to present data from Landmark survey on SBS

2026-04-23T11:25:41.000Z - 4 weeks ago

Ironwood to present data from Landmark survey on SBS


Ironwood price target raised to $10 from $8 at Citizens

2026-02-26T11:08:56.000Z - 3 months ago

Ironwood price target raised to $10 from $8 at Citizens


Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 8:30 AM EST - 3 months ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2025


Ironwood Pharmaceuticals Annual report: Q4 2025

Feb 25, 2026, 8:30 AM EST - 3 months ago

Ironwood Pharmaceuticals Annual report: Q4 2025


Ironwood Pharmaceuticals Earnings release: Q4 2025

Feb 25, 2026, 8:30 AM EST - 3 months ago

Ironwood Pharmaceuticals Earnings release: Q4 2025


Ironwood Pharmaceuticals Slides: Q4 2025

Feb 25, 2026, 8:30 AM EST - 3 months ago

Ironwood Pharmaceuticals Slides: Q4 2025


3 Stocks Trading Near $5 With Massive Earnings Upside

Feb 8, 2026, 8:28 AM EST - 3 months ago

3 Stocks Trading Near $5 With Massive Earnings Upside

BTG RIG


Craig-Hallum upgrades Ironwood to Buy following 2026 guidance

2026-01-05T12:37:19.000Z - 4 months ago

Craig-Hallum upgrades Ironwood to Buy following 2026 guidance


Ironwood upgraded to Buy from Hold at Craig-Hallum

2026-01-05T12:20:08.000Z - 4 months ago

Ironwood upgraded to Buy from Hold at Craig-Hallum


Ironwood upgraded to Outperform from Market Perform at Citizens

2026-01-05T10:15:33.000Z - 4 months ago

Ironwood upgraded to Outperform from Market Perform at Citizens


Ironwood price target raised to $5 from $3 at Wells Fargo

2026-01-04T23:25:05.000Z - 5 months ago

Ironwood price target raised to $5 from $3 at Wells Fargo


Why Did Ironwood Pharma Stock (IRWD) Jump 30% Today?

2026-01-02T17:29:08.000Z - 5 months ago

Why Did Ironwood Pharma Stock (IRWD) Jump 30% Today?

PFE


Ironwood Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

Ironwood Pharmaceuticals Earnings release: Q3 2025


Ironwood Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

Ironwood Pharmaceuticals Quarterly report: Q3 2025


Ironwood Pharmaceuticals Slides: Q3 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

Ironwood Pharmaceuticals Slides: Q3 2025


Ironwood Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

Ironwood Pharmaceuticals Quarterly report: Q2 2025


Ironwood Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

Ironwood Pharmaceuticals Earnings release: Q2 2025


Ironwood Pharmaceuticals Reports First Quarter 2025 Results

May 7, 2025, 7:05 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reports First Quarter 2025 Results


Ironwood Pharmaceuticals Quarterly report: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Quarterly report: Q1 2025


Ironwood Pharmaceuticals Earnings release: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Earnings release: Q1 2025


Ironwood Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Proxy statement: Proxy Filing


Ironwood Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Proxy statement: Proxy Filing


Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2024


Ironwood Pharmaceuticals Annual report: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Annual report: Q4 2024


Ironwood Pharmaceuticals Earnings release: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings release: Q4 2024


Ironwood Pharmaceuticals Transcript: Status Update

Jan 29, 2025, 4:30 PM EST - 1 year ago

Ironwood Pharmaceuticals Transcript: Status Update


Ironwood Pharmaceuticals Press release: Status Update

Jan 29, 2025, 4:30 PM EST - 1 year ago

Ironwood Pharmaceuticals Press release: Status Update


Ironwood Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q3 2024


Ironwood Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Quarterly report: Q3 2024


Ironwood Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings release: Q3 2024


Ironwood Pharmaceuticals Slides: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Slides: Q3 2024


Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Nov 7, 2024, 7:00 AM EST - 1 year ago

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results


Ironwood Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q2 2024


Ironwood Pharmaceuticals Quarterly report: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Ironwood Pharmaceuticals Quarterly report: Q2 2024


Ironwood Pharmaceuticals Earnings release: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Ironwood Pharmaceuticals Earnings release: Q2 2024


Ironwood Pharmaceuticals Slides: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Ironwood Pharmaceuticals Slides: Q2 2024


Ironwood Pharmaceuticals Reports Second Quarter 2024 Results

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reports Second Quarter 2024 Results


joemist1
joemist1 May. 25 at 12:59 AM
$IRWD Good evening bstrds. Are the mtha fcking shirt sellers here yet to fck up the share price? They better show up!
0 · Reply
StockTwitsGhost
StockTwitsGhost May. 24 at 5:15 PM
$IRWD Realistic PoA is 90%+. The only scenario for a CRL here is a manufacturing issue or a safety signal in the 2-5 age cohort data that nobody has flagged publicly. Neither has any visible evidence. The reality is the PDUFA shouldn’t move IRWD +/- 5% on approval or decline, but it often feel less like fundamentals are not in the drivers seat and more like a coordinated manipulation by the deeply insecure hedge fund guys with cool operator beards, elevator shoes, and a carefully curated “masculine” image for their Maine vaca homes. 🤷🏼‍♀️
0 · Reply
StockTwitsGhost
StockTwitsGhost May. 23 at 7:05 PM
$IRWD When the FDA approved the pediatric IBS-C indication in November 2025, IRWD moved roughly 9% close to close and about 15% intraday. The May PDUFA or CRL on the supplemental indication would likely pull shares up/down 8-10% given the ongoing FUD by the 🦄 brigade which includes the Maine short sellers. Also notably in November, neither AbbVie nor Ironwood issued a standalone press release for that approval either. There was no dedicated 8-K, no standalone Business Wire release, and no SEC filing on November 5 itself tied to the approval event, instead it was buried in IRWD Q3 2025 earnings press release filed as an 8-K Exhibit 99.1 on November 10, 2025. Compare that to the June 2023 pediatric FC approval, which both companies announced with dedicated PRs.
0 · Reply
revuelto
revuelto May. 23 at 10:26 AM
$IRWD extreme fud is largely priced in at these levels…approval I think is expected by the street…post June repayment the convertibles disappear cleaning up the balance sheet…this sentiment shift should get it to a more meaningful valuation (2x)…also, acquisition interest will be extremely strong after these events.
0 · Reply
noturfinancrbro
noturfinancrbro May. 23 at 6:26 AM
$IRWD do you expect any move after Pdufa Or is it already priced in,
0 · Reply
StMichaelTwits
StMichaelTwits May. 22 at 10:11 PM
$IRWD Pdufa pastries are always better in the morning with your caffe' This is getting approved.imo 💎💪
0 · Reply
StockTwitsGhost
StockTwitsGhost May. 22 at 5:28 PM
$IRWD NDA 202811/S-023 For you cyber sleuths, search NDA 202811/S-023 attention AbbVie Inc and watch for it to appear in the supplements table with an action date. Right now it shows nothing because it’s pending. The moment the FDA acts, approval or CRL, that entry will populate with an action date. The FDA database update will likely hit before or simultaneously with the AbbVie press release, and definitely before IRWD files an 8-K. It’s the most direct primary source you have. Check it Tuesday morning before the open. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
0 · Reply
StockTwitsGhost
StockTwitsGhost May. 22 at 4:03 PM
$IRWD If no action comes during business hours today, after hours is effectively off the table. The FDA issues approvals during normal business hours they don’t drop letters in the evening or on weekends. So Tuesday May 26 this is now the call. AbbVie will receive notification before Ironwood since they are the applicant so they could be sitting on a press release, holding it until Tuesday morning for a time release with IRWD for maximum market visibility. 80% Tuesday almost certainly before market open is our most likely window.
3 · Reply
UprootedData975
UprootedData975 May. 22 at 3:04 PM
$IRWD wonder when this will re-rate. even at a reasonable 6x multiple we're at double the current share price...
0 · Reply
UprootedData975
UprootedData975 May. 22 at 3:02 PM
$IRWD guessing we'll see PDUFA response Tuesday?
0 · Reply
StockTwitsGhost
StockTwitsGhost May. 22 at 6:16 AM
$IRWD Either there’s some serious misunderstanding or deliberate FUD circulating around the $200 million of 1.50% convertible senior notes due June 15 but management stated during Q1 call and I quote, “plan to repay the 2026 convertible note in cash at maturity in June” as well as “plan to use cash on hand and cash flows generated throughout 2026 to reduce our total debt balance”. Martini also stated the same in February. The key takeaway is: Management has explicitly guided that they expect to fully repay the $200M June 2026 converts in cash at maturity, rather than refinancing or settling in stock. https://earningscall.biz/e/nasdaq/s/irwd/y/2026/q/q1
1 · Reply
ASKING7
ASKING7 May. 21 at 9:37 PM
$IRWD also Clinical Operations Lead, Development Operations (Basel, Switzerland) is also taken out on the Job Posting, this is one of the most important positions for Star2, and I can only think of 4 possibilities. 1. M&A in progress 2. Star 2 has to be delayed as company needs to monitor the cash flow after 0.2B debt payment (Sliver as accountant really try to tighten the book right now) 3. CRO will handle it to save the cost 4. Job just being hired (low possibility) With today after hour Sec file 8K and Form regarding Silver, and no additional Sec file regarding Greg also (Greg seems like really giving up all the shares), this game is getting more blurry than ever. I need more Sec files if coming out in next few weeks to confirm more things.
1 · Reply
cert
cert May. 21 at 9:34 PM
$IRWD what are chances of PDUFA approval ?
3 · Reply
ASKING7
ASKING7 May. 21 at 8:42 PM
$IRWD FYI, Sec 8K out. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001446847/000110465926065140/tm2615121d1_8ka.htm
1 · Reply
Bio_Invest101
Bio_Invest101 May. 21 at 8:32 PM
$IRWD With $10 deal this interim CFO will get much richer soon on his 440K shares https://d18rn0p25nwr6d.cloudfront.net/CIK-0001446847/c29b03e5-15f8-455e-b215-bba0d407f9ff.pdf
0 · Reply
Bio_Invest101
Bio_Invest101 May. 21 at 8:28 PM
$IRWD Good sign !! On May 19, 2026, in connection with Mr. Silver’s new role as the Company’s interim chief financial officer and principal financial officer, the Committee approved a monthly interim assignment fee of $12,250 (the “Interim CFO Assignment Fee”) for Mr. Silver. Mr. Silver’s Interim CFO Assignment Fee will remain in place until the earlier of the Company’s appointment of a chief financial officer or the termination of the interim assignment for any other reason. In addition, on May 19, 2026, Mr. Silver received a grant of 25,000 restricted stock units (“RSUs”) representing the right to receive shares of the Company’s Class A common stock upon vesting of such awards granted under the Company’s 2019 Amended and Restated Equity Incentive Plan. The RSUs will vest over two years as to 50% of the RSUs on each approximate anniversary of the date of grant https://d18rn0p25nwr6d.cloudfront.net/CIK-0001446847/cffc10b9-d327-427c-a5a3-50fa51266048.pdf
1 · Reply
StockTwitsGhost
StockTwitsGhost May. 21 at 7:51 PM
$IRWD PDUFA on the ⏰
0 · Reply
Bio_Invest101
Bio_Invest101 May. 21 at 6:35 PM
$IRWD This Indian company has been rumored for 2-3 weeks to buy another IBSc/ckd drug maker ARDX but instead they got involved into a bidding war for Assertio and paid 35% over another winning bid in all cash deal. Very impressive https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-lifesciences-to-pursue-acquisitions-in-specialty-rare-diseases/articleshow/131205005.cms
0 · Reply
revuelto
revuelto May. 21 at 2:27 AM
$IRWD hey rumor mongers with loyal cult followings, do the community a solid and start floating Ironwood takeover rumors 😀
0 · Reply
revuelto
revuelto May. 20 at 8:04 PM
$IRWD the tape feels predictably bullish 🎉
0 · Reply
Bio_Invest101
Bio_Invest101 May. 20 at 5:04 PM
$IRWD Biotech M&A is still hot. Lilly is actively evaluating brenipatide (LY3537031) in clinical trials for adults with Irritable Bowel Syndrome with Constipation (IBS-C).CIC: Drug development in this category often overlaps with IBS-C, and Lilly is targeting the intersection of these bowel movement and constipation-related disorders. IBD (Inflammatory Bowel Disease): Lilly has a robust IBD drug development program, specifically targeting Crohn’s disease and ulcerative colitis. The company has developed Omvoh (mirikizumab) for moderate-to-severe IBD and expanded its portfolio with acquisitions like Morphic’s oral integrin therapy Maybe Lilly should add SBS ? https://www.fiercebiotech.com/biotech/busy-lilly-closes-202m-deal-preclinical-dna-delivery-biotech-engage
0 · Reply
StockTwitsGhost
StockTwitsGhost May. 20 at 4:58 PM
$IRWD A lot of small 🍆 energy around here.
0 · Reply